Sphera Funds Management’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
Other funds holding APRE
ACM
VPC
NCM
DP
Sphera Funds Management's APRE Position: Q2 2026 in Review
Sphera Funds Management held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 270,000 shares worth $217K. The position accounts for 0.03% of the portfolio, ranked #105.
Sphera Funds Management first reported a position in APRE in Q2 2020 and has held it in 11 quarters since. The position peaked at $6.14M in Q2 2020. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.
- Sphera Funds Management held 270,000 shares of Aprea Therapeutics worth $217K as of Q2 2026.
- Sphera Funds Management left its Aprea Therapeutics share count unchanged in Q2 2026.
- Aprea Therapeutics made up 0.03% of Sphera Funds Management's portfolio in Q2 2026, its #105 holding.
- Sphera Funds Management first reported a position in Aprea Therapeutics in Q2 2020 and has held it in 11 quarters since.
- Sphera Funds Management's Aprea Therapeutics position peaked at $6.14M in Q2 2020.
- 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.
Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.